Atara Biotherapeutics, Inc. (ATRA) EPS Estimated At $-1.14; Spartan Motors (SPAR) Has 0.85 Sentiment

February 27, 2018 - By Ellis Scott

Analysts expect Atara Biotherapeutics, Inc. (NASDAQ:ATRA) to report $-1.14 EPS on March, 8.They anticipate $0.51 EPS change or 80.95% from last quarter’s $-0.63 EPS. After having $-1.02 EPS previously, Atara Biotherapeutics, Inc.’s analysts see 11.76% EPS growth. The stock decreased 2.05% or $0.9 during the last trading session, reaching $43.1. About 328,576 shares traded. Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has declined 7.28% since February 27, 2017 and is downtrending. It has underperformed by 23.98% the S&P500.

Spartan Motors, Inc., through its subsidiaries, engineers, makes, and sells heavy-duty and custom vehicles in the United States, Canada, South America, and Asia. The company has market cap of $531.81 million. It operates through three divisions: Emergency Response Vehicles, Fleet Vehicles and Services, and Specialty Chassis and Vehicles. It has a 36.51 P/E ratio. The Emergency Response Vehicles segment offers emergency response chassis and vehicles, and aerial ladder components, as well as aftermarket repair parts and accessories under the Spartan ERV brand name.

Since January 1, 0001, it had 0 insider purchases, and 2 sales for $367,903 activity.

Analysts await Spartan Motors, Inc. (NASDAQ:SPAR) to report earnings on March, 1 before the open. They expect $0.09 earnings per share, up 125.00% or $0.05 from last year’s $0.04 per share. SPAR’s profit will be $3.16 million for 42.08 P/E if the $0.09 EPS becomes a reality. After $0.21 actual earnings per share reported by Spartan Motors, Inc. for the previous quarter, Wall Street now forecasts -57.14% negative EPS growth.

It closed at $15.15 lastly. It is down 45.41% since February 27, 2017 and is uptrending. It has outperformed by 28.71% the S&P500.

Silver Capital Management Llc holds 5.52% of its portfolio in Spartan Motors, Inc. for 124,109 shares. Pacific Ridge Capital Partners Llc owns 388,176 shares or 1.22% of their US portfolio. Moreover, Zuckerman Investment Group Llc has 0.7% invested in the company for 257,878 shares. The Wisconsin-based Heartland Advisors Inc has invested 0.5% in the stock. Oberweis Asset Management Inc, a Illinois-based fund reported 143,300 shares.

Since September 6, 2017, it had 0 insider buys, and 18 insider sales for $8.19 million activity. Ciechanover Isaac E. sold $938,459 worth of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) on Thursday, February 15. The insider MCGRATH JOHN sold $611,925. The insider Gallagher Carol Giltner sold $55,010. Haqq Christopher sold $91,800 worth of stock or 6,000 shares. 12,214 Atara Biotherapeutics, Inc. (NASDAQ:ATRA) shares with value of $464,210 were sold by Turner Heather D.

Among 7 analysts covering Atara Biotherapeutics (NASDAQ:ATRA), 5 have Buy rating, 1 Sell and 1 Hold. Therefore 71% are positive. Atara Biotherapeutics had 21 analyst reports since September 9, 2015 according to SRatingsIntel. Jefferies reinitiated the stock with “Buy” rating in Monday, October 24 report. The rating was downgraded by Citigroup on Thursday, February 15 to “Sell”. JMP Securities maintained Atara Biotherapeutics, Inc. (NASDAQ:ATRA) rating on Tuesday, December 15. JMP Securities has “Market Outperform” rating and $40 target. The firm earned “Sell” rating on Friday, August 19 by Citigroup. As per Thursday, September 15, the company rating was downgraded by Goldman Sachs. The company was initiated on Friday, October 9 by William Blair. Canaccord Genuity maintained it with “Buy” rating and $70.0 target in Tuesday, January 30 report. The firm has “Buy” rating by Jefferies given on Thursday, June 22. The rating was initiated by Canaccord Genuity with “Buy” on Wednesday, September 9. The firm earned “Sell” rating on Tuesday, December 15 by Citigroup.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: